Engineered exosomes for autoimmune disease tolerance induction in canine T1D models

Overview

Entelexo Biotherapeutics has developed a novel platform of engineered therapeutic exosomes designed to treat autoimmune diseases, with an initial focus on Type 1 Diabetes (T1D) in canine models. These tunable exosomes can simultaneously affect multiple types of immune cells, representing a potentially transformative approach to autoimmune disease treatment. The modular technology displays canine inhibitory molecules on the exosome surface, enabling the suppression of activated cells involved in T1D pathology while also inducing immune tolerance—a combination that could lead to curative outcomes rather than mere symptom management.

Technical specifications

• Modular exosome platform engineered to display inhibitory molecules tailored to canine immune cells
• Multi-target capability allowing simultaneous modulation of several immune cell types
• Dual mechanism of action combining suppression of activated pathogenic immune cells with induction of regulatory T cells for tolerance
• Proprietary assays using human or canine PBMCs (peripheral blood mononuclear cells) to evaluate and optimize drug candidate function
• Data-driven optimization approaches for rational design of therapeutic exosome candidates
• Pre-existing validation data demonstrating immune cell suppression and regulatory T cell induction using PBMC assays

Technology readiness level

The technology has achieved initial proof-of-concept with demonstrated ability to suppress immune cells and induce regulatory T cells using PBMC-based assays. The next development phase involves rationally designing therapeutic exosomes specifically targeting canine immune cells, followed by in vitro optimization using proprietary assays with human or canine PBMCs. Upon successful in vitro validation, the program will advance to canine animal studies. The platform is currently at an early-to-mid preclinical stage with strong foundational data supporting further development toward IND-enabling studies and eventual clinical translation.